



**The Clatterbridge
Cancer Centre**
NHS Foundation Trust

Clatterbridge Road
Bebington
Wirral
CH63 4JY

Tel: 0151 556 5000
Web: www.clatterbridgecc.nhs.uk

Date: 26 October 2020

Re: Freedom of Information Request
Ref: 224-2020

Thank you for your email dated the 2nd October, requesting information in relation to treatment of Lung and Urothelial cancer.

The information that you require is as follows:

I am researching the incidence and treatment of Lung and Urothelial cancer. Could you please answer the following three questions for patients treated by your trust?

Please note in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000. The areas where this exemption has been applied are shown below:

Q1. In the past 3 months, how many Urothelial cancer patients were treated with the following: **(Some patients may have had more than one treatment)**

- Atezolizumab: **45**
- Carboplatin with Gemcitabine: **105**
- Carboplatin with Paclitaxel: **0**
- Carboplatin single or in any other combination: **14**
- Cisplatin with Gemcitabine: **205**
- Cisplatin single or in any other combination: **11**
- Nivolumab: **138**
- MVAC with G-CSF: **0**
- Pembrolizumab: **54**
- Any other regimen including Paclitaxel: **13**

(Paclitaxel (2 or 3 weekly) = Exempt under Section 40: Personal Information, Paclitaxel 7 day = 9 and Paclitaxel 80mg/m2 day = Exempt under Section 40: Personal Information)

- Any other chemo regimen: **99**
- Other active systemic anti-cancer therapy [please state]: **509**
 - (EGFR) inhibitors: 10**
 - angiogenesis inhibitor: Exempt under Section 40: Personal Information**
 - monoclonal antibody: 106**
 - mTOR inhibitor: 21**
 - pan-FGFR inhibitor: Exempt under Section 40: Personal Information**
 - tyrosine kinase inhibitor: 368**
- Palliative care only: **Exempt under Section 40: Personal Information (CCC Palliative Care Team and no treatment)**

Q2. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with: **(Some patients may have had more than one treatment)**

- Afatinib: **24**
- Alectinib: **9**
- Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel: **6**
- Atezolizumab monotherapy: **32**
- Bevacizumab: **32**
- Brigatinib: **Exempt under Section 40: Personal Information**
- Ceritinib: **Exempt under Section 40: Personal Information**
- Crizotinib: **Exempt under Section 40: Personal Information**
- Dacomitinib: **0**
- Docetaxel monotherapy: **Exempt under Section 40: Personal Information**
- Durvalumab: **16**
- Erlotinib: **13**
- Gefitinib: **Exempt under Section 40: Personal Information**
- Gemcitabine: **0**
- Necitumumab: **0**
- Nintedanib with Docetaxel: **6**
- Nivolumab: **6**
- Osimertinib: **24**
- Paclitaxel: **Exempt under Section 40: Personal Information**
- Pembrolizumab chemo in combination: **42**
- Pembrolizumab monotherapy: **153**
- Pemetrexed: **Exempt under Section 40: Personal Information**
- Pemetrexed with Carboplatin: **18**
- Pemetrexed with Cisplatin: **Exempt under Section 40: Personal Information**
- Ramucirumab: **0**

- Vinorelbine and cisplatin/carboplatin: **24 (x12 Carboplatin + Vinorelbine and x12 Cisplatin + Vinorelbine)**
- Other: **56**
- Atezolizumab with Bevacizumab: **Exempt under Section 40: Personal Information**
- Carboplatin with Etoposide: **Exempt under Section 40: Personal Information**
- Carboplatin with Paclitaxel: **11**
- Cisplatin with Etoposide: **Exempt under Section 40: Personal Information**
- Dacomitinib: **Exempt under Section 40: Personal Information**
- Everolimus: **Exempt under Section 40: Personal Information**
- Gemcitabine with Carboplatin: **13**
- Lenvatinib/Placebo(LEAP006 Trial): **Exempt under Section 40: Personal Information**
- Lorlatinib: **Exempt under Section 40: Personal Information**
- Nintedanib: **Exempt under Section 40: Personal Information**
- Octreotide: **8**
- Palbociclib (Lung Matrix Trial): **Exempt under Section 40: Personal Information**
- Sirolimus: **Exempt under Section 40: Personal Information**

Q3. Could you please provide the total number of patients with any treatment in the last three months for: **(Below includes SACT & Radiotherapy)**

- Total non-small cell lung cancer (NSCLC): **543**
- Squamous non-small cell lung cancer (Sq NSCLC): **Please see table below***
- Non-squamous non-small cell lung cancer (Non-Sq NSCLC): **Please see table below***

***Histology of patients with Non-Small Cell Lung Cancer:**

Adenocarcinoma NOS:	305
Squamous cell carcinoma NOS:	112
Carcinoma NOS:	61
Non-small cell carcinoma:	21
Carcinoid tumour, malignant:	7
Adenosquamous carcinoma:	7
Acinar cell carcinoma:	6
Neuroendocrine carcinoma:	Exempt under Section 40: Personal Information
Keratinising squamous cell carcinoma:	Exempt under Section 40: Personal Information
Large cell neuroendocrine carcinoma:	Exempt under Section 40:

	Personal Information
Squamous cell carcinoma in situ NOS:	Exempt under Section 40: Personal Information
Mucinous adenocarcinoma:	Exempt under Section 40: Personal Information
Spindle cell carcinoma:	Exempt under Section 40: Personal Information
Adenocarcinoma, intestinal type:	Exempt under Section 40: Personal Information
Malignant tumour, clear cell type:	Exempt under Section 40: Personal Information

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.